I'm excited about the potential to harness precision genetic engineering to treat a variety of illnesses. Genedit's technology is a key enabler to deliver these therapies, which is why we led the Seed financing in 2016 as its First Believer.
Lots of news today from GenEdit! We announced our Series A financing and are providing a research update at the TIDES conference. With our Series A funding round of $26M, we’ll select initial therapeutic candidates for development that leverage our NanoGalaxy polymer nanoparticle delivery technology. Today at #TIDES we present data demonstrating that NanoGalaxy addresses historic challenges in genetic medicine delivery. We’re excited to be expanding the potential benefit of these medicines to many more patients than today. Interested in learning more? https://genedit.com/ #NanoGalaxy #geneticmedicine #genetherapy #geneediting #DNA #RNA #CRISPR #financing #researchdata #GenEdit
Unbelievable successes you having there Roelof Botha Well Done!
Having a first believer who continuously support is fantastic. Thanks!
Contributor
2yHi Roelof Botha (Different matter) - looking to connect, please connection request from your end. Best regards, Derrick Tsie